Expected effects
IMI will make Europe more attractive for pharmaceutical R&D investments and boost the competitiveness of European life science R&D. By directly addressing the challenges facing the pharmaceutical sector in Europe, IMI has the potential to:
- Modernise the development of medicines.
- Expand European expertise and know-how in new technologies to attract bio-medical R&D investment to Europe.
- Anchor R&D jobs in Europe and reverse the 'brain drain'.
- Enhance Europe's economy by strengthening the competitive position of smaller companies, enabling them to collaborate with a multitude of stakeholders.
An external evaluation of IMI's economic and societal effects was performed by a group of renowned external experts:
